Compare International Flavors & Fragrances Inc. Common Stock (IFF) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Flavors & Fragrances Inc. Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? International Flavors & Fragrances Inc. Common Stock trades at $91.38 (market cap $22.86B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.52 (market cap $977.37M). The key difference: International Flavors & Fragrances Inc. Common Stock is far larger — about 23.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and International Flavors & Fragrances Inc. Common Stock pays a 1.79% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold International Flavors & Fragrances Inc. Common Stock for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IFF | MRVI | |
|---|---|---|
Market Cap | $22.86B | $977.37M |
Volume | 2,182,561 | 2,742,564 |
Sector | Basic Materials | Health |
52-Week High | $89.60 | $9.00 |
52-Week Low | $61.49 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $28.54B | $1.08B |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IFF trades at $88.2, up 3.81% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $361 million in 2025 but returned to profitability in 2026 with $277 million net income. Recent news highlights product innovations like AQUASCENT™ and life-stage dairy insights. Analyst consensus is strongly bullish with a $95 price target, though valuation ratios like P/E of 80.92 appear elevated relative to earnings.
The outlook for IFF hinges on sustaining its 2026 profitability turnaround and executing growth initiatives. Investment opportunities include market leadership in flavors and fragrances and new technology launches. Key risks are high debt levels, competitive pressures, and sensitivity to consumer spending trends. The stock's upside is supported by analyst optimism but requires careful monitoring of earnings consistency.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About International Flavors & Fragrances Inc. Common Stock
International Flavors & Fragrances develops ingredients and solutions used in food, beverages, personal care, home care, health, and biosciences applications. Its portfolio includes flavors, fragrances, cultures, enzymes, and nutrition ingredients.
Read more on IFF →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
